Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
Study of Sacituzumab Govitecan in Patients With Solid Tumor

trialsTrialActive

Study of Sacituzumab Govitecan in Patients With Solid Tumor

A phase 2 trial of Sacituzumab govitecan in advanced solid tumours, run by Gilead Sciences, active and no longer recruiting.

Overview Connected5

Overview

Study of Sacituzumab Govitecan in Patients With Solid Tumor is a phase 2 interventional study registered as NCT05119907 by Gilead Sciences, with 53 participants enrolled, started 2021-10-12 and due to reach its primary completion in 2026-10. Interventions recorded: Sacituzumab Govitecan-hziy.

Setting

A Phase II Open Label Study of Sacituzumab Govitecan in Patients With Solid Tumor

Phase

Phase 2

Sponsor

Gilead Sciences

Registry

Started

2021-10-12

Enrolled

53 enrolled

Connected

Similar pages

Trial
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread) and the tag pipeline.
Trial
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Trial
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread) and the tag pipeline.
Trial
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Trial
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Shares Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Metastatic cancer (cancer that has spread), Antibody-drug conjugate (ADC) and the tag pipeline.
Trial
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Trial
Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.
Trial
Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC) and the tag pipeline.

cancers

Metastatic cancer (cancer that has spread)

technologies

Antibody-drug conjugate (ADC)Topoisomerase-I inhibitors (and ADC payloads)

drugs

ApprovedADC

Sacituzumab govitecan · Trodelvy

companies

Gilead Sciences (incl. Kite)

Evidence strength29/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 2+15
53 enrolled+9
No structured primary endpoint0
Result: active0
No independent replication recorded0
A linked product is approved+5

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-22 · Jude Gomila · Wave 2 corpus-only joins applied · diff · file

Sources & links

ClinicalTrials.gov NCT05119907

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Metastatic cancer (cancer that has spread)

Technologies

Antibody-drug conjugate (ADC)
Topoisomerase-I inhibitors (and ADC payloads)

Products

Sacituzumab govitecan

Companies

Gilead Sciences (incl. Kite)

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Study of Sacituzumab Govitecan in Patients With Solid Tumor

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct05119907/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct05119907.

WebMCP tools registered on this page: onco_search, onco_get_entity.